Case Reports {#sec1_1}
============

Case 1 {#sec2_1}
------

A 68-year-old Japanese woman with cerebral infarction was diagnosed with multiple myeloma IgGκ, Durie-Salmon stage IIIA, ISS II. At diagnosis, she had a performance status (PS) of 2; bone marrow plasmacytosis was 34.6% and serum IgG was 7,169 mg/dL. She had anemia (Hb 8.0 g/dL) and osteolysis bone lesion. No cytogenetic abnormalities were detected by fluorescent in situ hybridization (FISH). She was started with melphalan and prednisolone (MP), and plateau phase was achieved after 6 courses of MP. After plateau, MP was given intermittently until progression of disease. During the treatment period, she had no severe adverse events and maintained a stable disease (SD) without deep response. Even after the patient was approved to receive novel agents, she refused intensive treatment because of cerebral infarction sequelae. She survived for 6.7 years (Table [1](#T1){ref-type="table"}).

Case 2 {#sec2_2}
------

A 78-year-old Japanese man was diagnosed with multiple myeloma IgGκ, Durie-Salmon stage IIIB, ISS II. At diagnosis, he had a PS of 1; bone marrow plasmacytosis was 12.7% and serum IgG was 3,164 mg/dL. He had mild anemia (Hb 11.8 g/dL), osteolysis bone lesion, and renal dysfunction (eGFR 52.1 mL/min/1.73 m^2^). No cytogenetic abnormalities were detected by FISH. He was started with MP and it was administered intermittently until progression of disease. During the treatment period, he did not have any severe adverse events and maintained SD without deep response. Even after approval of novel agents, he refused to use them because of old age. He survived for 7.8 years (Table [1](#T1){ref-type="table"}).

Case 3 {#sec2_3}
------

A 73-year-old Japanese woman was diagnosed with symptomatic multiple myeloma, developed from smoldering myeloma, with IgAλ, Durie-Salmon stage IIIA, ISS II. At diagnosis, she had a PS of 0; bone marrow plasmacytosis was 6.4% and serum IgA was 1,503 mg/dL. She had mild anemia (Hb 11.3 g/dL), lumbar compression fracture, and renal dysfunction (eGFR 49.8 mL/min/1.73 m^2^). The cytogenetic abnormalities were MAF:2/IGH:2 (19%) and FGFR3: 2/IGH:2 (20%) as detected by FISH. Colon cancer was also found and she underwent operative treatment. After the operation, she refused treatment for multiple myeloma. She has been observed and has only been given bisphosphonate. She has been in SD without treatment for 8.7 years (Table [1](#T1){ref-type="table"}).

Case 4 {#sec2_4}
------

A 79-year-old Japanese woman with high blood pressure and chronic heart disease was diagnosed with symptomatic multiple myeloma IgG kappa, Durie-Salmon stage IIIA, ISS II. At diagnosis, she had PS of 0. She had anemia (Hb 9.4 mg/dL), osteolysis bone lesion, and renal dysfunction (eGFR 56.9 mL/min/1.73 m^2^). She refused invasive examination and treatment because of old age. She also refused to undergo a bone marrow examination. Thus, we diagnosed her with symptomatic myeloma from the result of peripheral blood tests and the presence of bone disease. MP was started and has been continued intermittently. Even after approval of novel agents, she refused to use them. During the treatment period, she had no severe adverse events and has maintained SD without deep response. She has been in SD for 10.6 years (Table [1](#T1){ref-type="table"}).

Discussion {#sec1_2}
==========

The recent development of novel agents has markedly improved the prognosis of multiple myeloma. The treatment for symptomatic myeloma aiming for deep response is recommended because it will lead to better prognosis. Even for transplant-ineligible elderly patients, the use of novel agents is still recommended to achieve deep response. However, in clinical practice, clinicians sometimes encounter patients who show long-term prognosis without deep response. These cases have been recognized among clinicians and several reports have been published. Merchionne et al. \[[@B1]\] reported 21 long-term survivors who were treated with conventional chemotherapy without autologous stem cell transplant. Among these patients, the complete response (CR) rate was not correlated with overall survival (OS). Furthermore, patients with SD revealed as good a prognosis as CR or partial response (PR) patients.

Paiva et al. \[[@B2]\] used multiparameter flow cytometry to distinguish a MGUS (monoclonal gammopathy of undetermined significance)-like signature. The authors concluded that multiple myeloma cases with an MGUS-like signature had better prognosis and that those patients did not achieve CR and might have returned into MGUS. The authors reported that the prognosis of these patients was not dependent on the depth of response and their time to progression (TTP) was 59% at 10 years. Sigurdardottir et al. \[[@B3]\] reported that myeloma progression from MGUS revealed better survival (median 2.8 years) than multiple myeloma without MGUS (2.1 years).

We speculated that our indolent myeloma patients might have been maintaining a balance between disease progression and effectiveness of chemotherapy. We hypothesized that this group might have developed symptomatic multiple myeloma slowly from MGUS or smoldering multiple myeloma (SMM) and might have immediately returned to MGUS or SMM by conventional therapy. We speculate that the underlying mechanism may be as follows. Multiple myeloma is a heterogeneity common characteristic and it is explained according to Darwinian principles: clonal evolution underlines disease progression and relapse \[[@B4]\]. In this respect, there is the potential for differential responses within the tumor clone and for the selection and expansion of resistant subclones. The posttreatment progression of the disease will be determined by which myeloma clones, either the more indolent clones or the more aggressive clones, repopulate the plasma cell niche in the bone marrow. In the case of the very slow progression group, we speculate that more indolent clones became dominant and more aggressive clones were eradicated by the initial therapy.

We believe that these indolent myeloma cases do not need intensive chemotherapy. Since novel agents have improved better outcome in recent clinical trials, these agents have been recommended for use \[[@B5], [@B6]\]. However, this strategy might be excessive in indolent myeloma patients. For elderly patients, aggressive treatment intervention might cause infection and shorten the prognosis. Moreover, making things more complicated is the fact that the treatment is started uniformly in the presence of CRAB (hypercalcemia, renal failure, anemia, bone disease) according to the guidelines. Among CRAB, it is speculated that anemia and renal failure have poor subjective symptoms, and these factors might overlap, in contrast to myeloma. Together, this suggests that treatment intervention criteria should be carefully developed.

Our cases started treatment of an initial induction therapy before approval of novel agents for use. During the treatment course, the patients received approval to begin treatment with novel agents; however, the patients\' conditions were already stable and the patients did not want to switch treatments.

In conclusion, here we identified a patient group of symptomatic but indolent multiple myeloma that remained in SD with conventional therapies. These findings suggest that intensive treatment may not necessarily benefit all transplant-ineligible myeloma patients. Further studies should focus on identifying the patient group that does not need intensive treatment. One challenge is how to evaluate indolent myeloma at the time of diagnosis, as at present, there is no way to judge indolent myeloma by general examination. In addition, no trials have researched or identified prognosis factors in myeloma. However, it might be helpful to observe the clinical course or response to the treatment. This is close to the experience value of clinicians and depends on the competence of the clinicians to accurately judge the patient\'s condition and select treatment. Further investigations are needed to identify molecular, genetic, and biological parameters to determine indolent myeloma.
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###### 

Patients\' characteristics

  Case   Sex   Age, years   PH             Survival, years   Outcome   Isotype   BJP   PS   ISS   DS   1st Tx   Response   MDE                 Prior status
  ------ ----- ------------ -------------- ----------------- --------- --------- ----- ---- ----- ---- -------- ---------- ------------------- --------------
  1      F     68           CI             06.7              dead      IgGκ      \+    0    2     3A   MP       SD         anemia/bone         --
  2      M     78           HBP            07.4              dead      IgGκ      \+    1    2     3B   MP       SD         anemia/renal/bone   --
  3      F     73           Colon cancer   08.7              alive     IgAλ      −     0    2     3A   no Tx    SD         anemia/renal/bone   smoldering
  4      F     79           HBP/CHF        10.6              alive     IgGκ      \+    0    2     3A   MP       SD         anemia/renal/bone   --

PH, past history; BJP, Bence-Jones protein; PS, performance status; ISS, international staging system; DS, Durie-Salmon staging system; Tx, treatment; MDE, myeloma-defining event; F, female; M, male; CI, cerebral infarction; HBP, high blood pressure; CHF; chronic heart failure; MP, melphalan and prednisolone; SD, stable disease.
